Short-Term Therapy for Patients with Hepatitis C Virus Genotype 2 or 3 Infection

ISSN： 0012-6667

Source： Drugs, Vol.66, Iss.14, 2006-01, pp. : 1807-1815

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

For patients with hepatitis C virus (HCV) infection who respond rapidly to peginterferon-α-2a, 8 weeks of therapy is as effective as a 24 weeks

Inpharma, Vol. 1, Iss. 1639, 2008-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Population Pharmacokinetics and Pharmacodynamics of Albinterferon Alfa-2b in Patients Treated for Hepatitis C Virus Genotype 2/3

Anti-Infective Agents, Vol. 12, Iss. 1, 2014-01 ,pp. : 58-67

Bentham Science Publishers

Access to resources Recommend Favorite

Population Pharmacokinetics and Pharmacodynamics of Albinterferon Alfa-2b in Patients Treated for Hepatitis C Virus Genotype 2/3

By Yu Jing Sun Haiying Pang Maria Chuang Wan-Long Sarin Shiv K. Flisiak Robert Stein Daniel S.

Anti-Infective Agents, Vol. 12, Iss. 1, 2014-01 ,pp. : 58-67

Bentham Science Publishers

Access to resources Recommend Favorite

Financial Impact of Two Different Ways of Evaluating Early Virological Response to Peginterferon- -2b Plus Ribavirin Therapy in Treatment-Naive Patients with Chronic Hepatitis C Virus Genotype 1

By Buti Maria

PharmacoEconomics, Vol. 23, Iss. 10, 2005-01 ,pp. : 1043-1055

Adis International

Access to resources Recommend Favorite

Bezafibrate therapy reduces serum hepatitis C virus (HCV) RNA titre in patients with chronic HCV infection

Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite